Table 2.

Cross‐Validated Performance Measures of Elastic Net Models, Including Clinical Characteristics and Plasma Proteins, to Discriminate ACMP Cases From Anthracycline‐Treated Controls

Performance measure	NT‐proBNP+clinical characteristics*	All proteins+clinical characteristics*	Wilcoxon test P value
Main analysis in all participants (n=57)
AUC (95% CI)	0.75 (0.71–0.80)	0.78 (0.72–0.83)	0.766
Sensitivity (95% CI)	0.86 (0.82–0.90)	0.87 (0.83–0.91)	…
Specificity (95% CI)	0.78 (0.82–0.90)	0.78 (0.72–0.84)	…
Analysis in asymptomatic cases without heart failure (n=41)
AUC (95% CI)	0.50 (0.50–0.62)	0.75 (0.63–0.75)	0.022
Sensitivity (95% CI)	0.89 (0.84–0.93)	0.90 (0.86–0.94)	…
Specificity (95% CI)	0.61 (0.54–0.68)	0.69 (0.62–0.76)	…

Performance measures are reported for elastic net models fitted in all participants and in asymptomatic cases without heart failure. ACMP indicates anthracycline‐related cardiomyopathy; AUC, area under the receiver operating characteristic curve; and NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.

^*Clinical characteristics included sex, age at cancer diagnosis, time since cancer diagnosis, anthracycline/mitoxantrone dose (doxorubicin equivalents), and chest‐directed radiotherapy dose. Sensitivities and specificities are reported at the threshold maximizing the sum of sensitivity and specificity.